Discover the latest advancements in small cell lung cancer through Novotech CRO’s in-depth disease analysis. Gain valuable insights into novel therapies, ongoing clinical trials, and future ...
Boehringer Ingelheim’s blockbuster Ofev could be set for an expanded indication in children and adolescents with fibrosing ILDs.
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended Eli Lilly’s Omvoh (mirikizumab) for approval in the European Union (EU) to treat adults with ...
New HTA statistics produced by Denmark’s Medicinrådet for 2024 have prompted GlobalData to assess evolving HTA trends in the Nordic market.
AbbVie has entered into a definitive agreement to acquire Nimble Therapeutics in a deal valued at $200m in cash.
Ulefnersen Sodium is an antisense oligonucleotide commercialized by Ionis Pharmaceuticals, with a leading Phase III program in Amyotrophic Lateral Sclerosis.
Risk adjusted net present value: What is the current valuation of Artiva Biotherapeutics’s GCC-4001?
GCC-4001 is a cell therapy commercialized by Artiva Biotherapeutics, with a leading Phase II program in B-Cell Non-Hodgkin Lymphoma.
NBI-1076986 is a small molecule commercialized by Neurocrine Biosciences, with a leading Phase I program in Movement Disorders.
Eloralintide is a synthetic peptide commercialized by Eli Lilly and Co, with a leading Phase II program in Obesity.
PM-359 is a gene-modified cell therapy commercialized by Prime Medicine, with a leading Phase II program in Chronic Granulomatous Disease.
Cannabidiol 1 is a small molecule commercialized by Cardiol Therapeutics, with a leading Phase II program in Pericarditis.
IMM-1-104 is a small molecule commercialized by Immuneering, with a leading Phase II program in Pancreatic Cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback